Update: See our June 10, 2020 article here describing the amendments extending the deadline, and our articles here and here regarding the amendments further deferring the coming into force date until July 1, 2021, and our article reporting a further deferral to January 1, 2022 here.
Further to our last update on the amendments to the Patented Medicines Regulations (see here) and related Guidance (see here), the Patented Medicine Prices Review Board (PMPRB) has today announced that:
- The coming into force date of the amended Patented Medicines Regulations will now be January 1, 2021; and
- A revised set of draft Guidelines will be published the week of June 15, 2020 followed by a 30-day consultation period.
The most immediate and practical impact of this change is that reporting requirements due by July 30, 2020 of sales and pricing information for the period from January 1, 2020 to June 30, 2020 will clearly be governed by the current Regulations.
Should you have any questions on the foregoing, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
